A new business merger has just been completed within the 3D printing industry, with a real power couple joining together via Mach7 and 3D Medical. Just announced as a done deal, the merger will allow for quite the solid and symbiotic combination of services and products as they begin acting as one, offering advanced medical imaging solutions to their united list of customers spanning five continents. Now known as Mach7 Technologies Limited, the new company will begin trading on the Australian Stock Exchange under the symbol M7T.
If you were looking for two companies to blend, it would certainly be hard to find a better fit on paper or in terms of things in common, as on their own 3D Medical was known for 3D printing patient-specific models of bones and organs for a wide range of doctors and surgeons, while Mach 7 has been in the business of supplying medical imaging data. We reported on this impending deal previously as the two companies began the process last fall. Now, after just completing the $60 million deal, they will be headquartered in Melbourne, Australia, with the US-based Mach 7 taking on 3D Medical as a subsidiary—now formally owned by the new Mach7 Technologies Limited.
Shareholders of 3D Medical and Mach7 Technologies approved the merger on March 31, 2016, including the name change to Mach7 Technologies Limited. Albert Liong was appointed managing director and CEO, Jenni Pilcher becomes the global CFO and CEO of Australia operations and Ken Poutakidis was appointed non-executive chairman.
3D Medical has been known around the world and in Australia as a pioneer in 3D printing. They’ve been at the forefront of personalizing healthcare offering both technologies and solutions that should continue to be a large part of a very positive future for health professionals and patients.
“Our commitment to customer-driven design remains the core of our culture and the soul of our business philosophy,” commented Albert Liong, managing director and CEO of Mach7. “We are a company born of innovation and growing through extraordinary collaboration to bring advanced enterprise data management and medical solutions to our expanding network of customers, healthcare communities and globally connected healthcare ecosystems.”
With this merger, Mach7 will gain greater entrance to global capital markets, while still keeping a focused, corporate presence. Also on a very positive note for all involved, they’ve announced that both previous entities will be retaining their employee bases in engineering, customer sales, support, marketing, and service relationships. Mach7 will also keep offices open in Burlington, VT for development, sales, services, and support—with an extended focus on creating more business throughout Australia, New Zealand and Western Europe.
“We’ve long admired Mach7’s global success,” commented Jenni Pilcher, Mach7 CFO and CEO Australia operations. “The combined strength of our two organizations will enhance our ability to serve a large healthcare market with ground-breaking medical technology applications for improved patient care.”
As a new company, Mach7 Technologies will provide enterprise imaging solutions to:
- Unlock patient data
- Unleash care intelligence
- Shift management, sharing, and use of medical imaging for powering the healthcare ecosystem
Together both companies will be able to continue offering medical 3D printing as well as distributing synergistic technologies that even include holographic projection. Their products continue to be unique in that they are able to add to data already produced by traditional imaging methods and allow for significantly better patient outcomes, as well as offering more affordability. We’ll be excited to continue following them as they forge ahead as Mach7 Technologies Limited. What do you think of this new merger in the 3D Printing Industry? Discuss in the Mach7 Technologies forum over at 3DPB.com.
You May Also Like
A Guide to Bioprinting: Understanding a Booming Industry
The success of bioprinting could become the key enabler that personalized medicine, tissue engineering, and regenerative medicine need to become a part of medical arsenals. Breakthroughs in bioprinting will enable...
Cell Culture Bioreactor for Tissue Engineering
Researchers from the US and Portugal are refining tissue engineering applications further, releasing the findings of their study in the recently published ‘A Multimodal Stimulation Cell Culture Bioreactor for Tissue...
3D Printing for Nerve Regeneration: Gelatin Methacrylate-Based Nerve Guidance Conduits
Chinese researchers delve deeply into tissue engineering, releasing the findings of their recent study in ‘3D printing of gelatin methacrylate-based nerve guidance conduits with multiple channels.’ While there have been...
China: Bioprinting Polycaprolactone/Silk Fibroin Scaffolds to Improve Meniscus Regeneration
Researchers from China are hoping to improve medical outcomes for patients dealing with knee joint issues. Their recent study, ‘Biomechanically, structurally and functionally meticulously tailored polycaprolactone/silk fibroin scaffold for meniscus...
View our broad assortment of in house and third party products.